Genedrive Regulatory News (GDR)

28 Nov 2008 07:30



]

Epistem Holdings plc

("Epistem" or "the Company")

Change of Adviser

Amendment to Articles of Association

and 

Notification re Schedule 2 paragraph (g) of the AIM Rules

Epistem (LSE: EHP), the UK biotechnology and contract research company, is pleased to announce the appointment with immediate effect of Piper Jaffray Ltd. as Nominated Adviser and sole broker to the Company. 

The Company announces that following the AGM held on 26th November 2008, the articles of association of the Company were amended by the insertion of the new following article 48:

"Subject always to the provisions of the Companies Act 2006, the board of directors of the Company from time to time may authorise any matter which would, if not so authorised, result in a director infringing his duty under section 175 of the Companies Act 2006 to avoid a situation in which he has, or can have a direct or indirect interest that conflicts or possibly may conflict with the interests of the Company."

All resolutions proposed at the AGM were duly passed.

The Company also announces that Mr. Matthew Walls, the Company's Chief Executive Officer, was previously a director of Zylepsis Limited ("Zylepsis") which went into administrative receivership on 3 October 2003. Mr. Walls gave notice of his resignation from Zylepsis on 10 April 2003 in order to pursue other career opportunities. Having worked an agreed period of notice, Mr. Walls ceased to be an employee of Zylepsis on 10 June 2003, at which date he also ceased to be a director of Zylepsis. The administrative receivership is still ongoing and Mr. Walls has not been the subject of any public criticism in connection with this event.

For further information please contact: